Clearside Biomedical (CLSD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts CLSD Hot Sheet
Join SI Premium – FREE
Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $410 thousand.
For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Williams Trading Downgrades Birkenstock Holding plc (BIRK) to Sell, 'Stock Less Comfortable than the Shoes'
- ProLogis (PLD) PT Lowered to $150 at BMO Capital
- VCI Global posts revenue drop and net loss in 1H2026 amid pivot
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
